X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ciclosporin
Therapeutic Area: Ophthalmology Product Name: Verkazia
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
Verkazia is a prescription-only, uniquely-formulated oil-in-water cationic emulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fursultiamine
Therapeutic Area: Ophthalmology Product Name: Alinamin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 24, 2020
Details:
The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxymetazoline
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RVL Pharmaceuticals
Deal Size: $89.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement July 28, 2020
Details:
Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
